PMID- 37559236
OWN - NLM
STAT- MEDLINE
DCOM- 20240507
LR  - 20240507
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
VI  - 20
IP  - 6
DP  - 2024
TI  - Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates 
      of Clinical and Pre-clinical Evidence.
PG  - e090823219597
LID - 10.2174/1573399820666230809152148 [doi]
AB  - Cardiovascular complications and renal disease is the growing cause of mortality 
      in patients with diabetes. The subversive complications of diabetes such as 
      hyperglycemia, hyperlipidemia and insulin resistance lead to an increase in the 
      risk of myocardial infarction (MI), stroke, heart failure (HF) as well as chronic 
      kidney disease (CKD). Among the commercially available anti-hyperglycemic agents, 
      incretin-based medications appear to be safe and effective in the treatment of 
      type 2 diabetes mellitus (T2DM) and associated cardiovascular and renal disease. 
      Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been shown to be 
      fruitful in reducing HbA1c, blood glucose, lipid profile, and body weight in 
      diabetic patients. Several preclinical and clinical studies revealed the safety, 
      efficacy, and preventive advantages of GLP-1RAs against diabetes- induced 
      cardiovascular and kidney disease. Data from cardio-renal outcome trials had 
      highlighted that GLP-1RAs protected people with established CKD from significant 
      cardiovascular disease, lowered the likelihood of hospitalization for heart 
      failure (HHF), and lowered all-cause mortality. They also had a positive effect 
      on people with end-stage renal disease (ESRD) and CKD. Beside clinical outcomes, 
      GLP-1RAs reduced oxidative stress, inflammation, fibrosis, and improved lipid 
      profile pre-clinically in diabetic models of cardiomyopathy and nephropathy that 
      demonstrated the cardio-protective and reno-protective effect of GLP-1RAs. In 
      this review, we have focused on the recent clinical and preclinical outcomes of 
      GLP-1RAs as cardio-protective and reno-protective agents as GLP-1RAs medications 
      have been demonstrated to be more effective in treating T2DM and diabetes-induced 
      cardiovascular and renal disease than currently available treatments in clinics, 
      without inducing hypoglycemia or weight gain.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Seksaria, Sanket
AU  - Seksaria S
AD  - Department of Pharmacology, ISF College of Pharmacy, GT Road, GhalKalan, Moga 
      142001, Punjab, India.
AD  - Department of Pharmacy, Sanaka Educational Trust's Group of Institutions, 
      Malandighi, Durgapur 713212, India.
FAU - Dutta, Bhaskar Jyoti
AU  - Dutta BJ
AD  - Department of Pharmacology, ISF College of Pharmacy, GT Road, GhalKalan, Moga 
      142001, Punjab, India.
AD  - Department of Pharmacology and Toxicology, National Institute of Pharmaceutical 
      Education and Research, Hajipur 844102, Bihar, India.
FAU - Kaur, Mandeep
AU  - Kaur M
AD  - Department of Pharmacology, ISF College of Pharmacy, GT Road, GhalKalan, Moga 
      142001, Punjab, India.
FAU - Gupta, Ghanshyam Das
AU  - Gupta GD
AD  - Department of Pharmacology, ISF College of Pharmacy, GT Road, GhalKalan, Moga 
      142001, Punjab, India.
FAU - Bodakhe, Surendra H
AU  - Bodakhe SH
AD  - Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), 
      Bilaspur 495009, Chhattisgarh, India.
FAU - Singh, Amrita
AU  - Singh A
AD  - Department of Pharmacology, ISF College of Pharmacy, GT Road, GhalKalan, Moga 
      142001, Punjab, India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
SB  - IM
MH  - Humans
MH  - *Glucagon-Like Peptide-1 Receptor/agonists
MH  - *Diabetes Mellitus, Type 2/drug therapy/complications
MH  - *Hypoglycemic Agents/therapeutic use
MH  - *Diabetic Nephropathies/drug therapy
MH  - Animals
MH  - Cardiovascular Diseases/prevention & control/etiology
MH  - Diabetic Cardiomyopathies/prevention & control/drug therapy
MH  - Incretins/therapeutic use
MH  - Renal Insufficiency, Chronic/drug therapy/complications
OTO - NOTNLM
OT  - GLP-1RAs
OT  - SIRT1
OT  - TGF-beta
OT  - Type 2 diabetes mellitus
OT  - cardio-renal diseases
OT  - cardiovascular complications.
EDAT- 2023/08/10 06:42
MHDA- 2024/05/07 06:43
CRDT- 2023/08/10 00:43
PHST- 2023/01/06 00:00 [received]
PHST- 2023/06/08 00:00 [revised]
PHST- 2023/06/30 00:00 [accepted]
PHST- 2024/05/07 06:43 [medline]
PHST- 2023/08/10 06:42 [pubmed]
PHST- 2023/08/10 00:43 [entrez]
AID - CDR-EPUB-133503 [pii]
AID - 10.2174/1573399820666230809152148 [doi]
PST - ppublish
SO  - Curr Diabetes Rev. 2024;20(6):e090823219597. doi: 
      10.2174/1573399820666230809152148.